Stocks and Investing
Stocks and Investing
Mon, April 1, 2013
[ 08:30 AM ] - WealthMakers
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 05:45 AM ] - WOPRAI
[ 04:30 AM ] - Market Wire
[ 01:46 AM ] - WOPRAI
[ 01:46 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
Sumant Kulkarni Maintained (BIIB) at Strong Buy with Increased Target to $206 on, Apr 1st, 2013
Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $200 to $206 on, Apr 1st, 2013.
Sumant has made no other calls on BIIB in the last 4 months.
There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
- Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
These are the ratings of the 3 analyists that currently disagree with Sumant
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $188 on, Monday, March 25th, 2013
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $200 on, Monday, March 4th, 2013
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013